Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Sara Alkner"'
Autor:
Michael Lempart, Martin P. Nilsson, Jonas Scherman, Christian Jamtheim Gustafsson, Mikael Nilsson, Sara Alkner, Jens Engleson, Gabriel Adrian, Per Munck af Rosenschöld, Lars E. Olsson
Publikováno v:
Radiation Oncology. 17
Background Delineation of organs at risk (OAR) for anal cancer radiation therapy treatment planning is a manual and time-consuming process. Deep learning-based methods can accelerate and partially automate this task. The aim of this study was to deve
Autor:
Sara Alkner, Christian Jamtheim Gustafsson, Minna Lerner, Lars E. Olsson, Joakim Medin, Carl Siversson
Publikováno v:
Radiation Oncology (London, England)
Radiation Oncology, Vol 16, Iss 1, Pp 1-11 (2021)
Radiation Oncology, Vol 16, Iss 1, Pp 1-11 (2021)
Background Most studies on synthetic computed tomography (sCT) generation for brain rely on in-house developed methods. They often focus on performance rather than clinical feasibility. Therefore, the aim of this work was to validate sCT images gener
Autor:
L. M. Fredrik Leeb-Lundberg, Christian Ingvar, Ulrik Narbe, Carina Forsare, Kristina Lövgren, Sara Alkner, Mårten Fernö, Lisa Rydén, Martin Sjöström, Pär-Ola Bendahl
Publikováno v:
Breast Cancer Research and Treatment
Purpose According to the 2017 St Gallen surrogate definitions of the intrinsic subtypes, Ki67, progesterone receptor (PR) and Nottingham histological grade (NHG) are used for prognostic classification of estrogen receptor (ER) positive/HER2-negative
Publikováno v:
Cancer Research. 79:PD8-11
Background: Adjuvant locoregional radiotherapy (LRRT) reduces risk of locoregional failures (LRF) and improves survival for node positive breast cancer (BC) patients. However, LRRT increases the risk for toxicity as edema in the arm, lung cancer and
Autor:
Julia, Tutzauer, Martin, Sjöström, Pär-Ola, Bendahl, Lisa, Rydén, Mårten, Fernö, L M Fredrik, Leeb-Lundberg, Sara, Alkner
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231786 (2020)
PLoS ONE
PLoS ONE
Background G protein-coupled estrogen receptor (GPER), or G protein-coupled receptor 30 (GPR30), is reported to mediate non-genomic estrogen signaling. GPR30 associates with breast cancer (BC) outcome and may contribute to tamoxifen resistance. We in
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 12, p e0226150 (2019)
PLoS ONE, Vol 14, Iss 12, p e0226150 (2019)
Background: Adjuvant endocrine treatment improves survival after estrogen receptor (ER) positive breast cancer. Recurrences occur, and most patients with metastatic breast cancer develop treatment resistance and incurable disease. An influential fact
Autor:
Kristina Lövgren, Mårten Fernö, Martin Sjöström, Lisa Rydén, P-O Bendahl, Sara Alkner, Ulrik Narbe, Carina Forsare, Christian Ingvar, Flm Leeb-Lundberg
Publikováno v:
Cancer Research. 78:P1-07
Background: Estrogen receptor (ER) positive HER2-negative breast cancer comprises 75–80% of all breast cancer. This fraction is even higher (>90%) in invasive lobular carcinoma (ILC). According to the St Gallen surrogate definitions of the intrinsi
Autor:
Per Karlsson, Jamila Adra, Elisabeth Kjellén, Sara Alkner, Fredrika Killander, Erik Holmberg, Dan Lundstedt, Mahnaz Haghanegi
Publikováno v:
International journal of radiation oncology, biology, physics. 105(2)
Purpose: To investigate incidence and location of locoregional recurrence (LRR) in patients who have received postoperative locoregional radiation therapy (LRRT) for primary breast cancer. LRR-position in relation to applied radiotherapy and the prim
Publikováno v:
European Journal of Cancer; 51(16), pp 2304-2313 (2015)
Aim A contralateral breast cancer (CBC) is today treated as an independent primary tumour, although recent data suggest risk and prognosis of CBC to be influenced by characteristics of and treatment given for the first tumour (BC1). We hereby investi
Autor:
Martin Sjöström, Mårten Fernö, Fredrik Leeb-Lundberg, Sara Alkner, Julia Tutzauer, Pär-Ola Bendahl, Lisa Rydén
Publikováno v:
Cancer Research. 80:P6-05
Introduction - G protein-coupled estrogen receptor (GPER), or GPR30, is a membrane receptor reported to mediate rapid, non-genomic estrogen responses. Multiple studies suggest that GPR30 expression associates with breast cancer outcome, although the